BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539


View Clinical Trials from BioPharm Insight

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

 Key Statistics

Ownership: Public

Web Site: Halozyme Therapeutics, Inc.
Employees: 152
Symbol: HALO

 Company News
Halozyme Therapeutics, Inc. (HALO) Strikes $581 Million R&D Pact With Johnson & Johnson (JNJ) 12/17/2014 9:02:32 AM
Halozyme Therapeutics, Inc. (HALO) Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting 12/12/2014 7:55:46 AM
Halozyme Therapeutics, Inc. (HALO) To Present At The 25th Annual Oppenheimer Healthcare Conference 12/5/2014 12:49:01 PM
Halozyme Therapeutics, Inc. (HALO) To Present At The Piper Jaffray Healthcare Conference 11/26/2014 5:58:35 AM
Halozyme Therapeutics, Inc. (HALO) Reports Third Quarter 2014 Financial Results 11/11/2014 7:51:17 AM
Halozyme Therapeutics, Inc. (HALO) To Present At The Credit Suisse Healthcare Conference 11/6/2014 7:39:53 AM
Halozyme Therapeutics, Inc. (HALO) To Host Third Quarter 2014 Financial Results Conference Call 11/4/2014 8:16:06 AM
Halozyme Therapeutics, Inc. (HALO) Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant 10/20/2014 9:03:50 AM
Halozyme Therapeutics, Inc. (HALO) Announces Podium Presentation On PEGPH20 At The New York Academy of Sciences 10/9/2014 9:30:49 AM
Halozyme Therapeutics, Inc. (HALO) Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20 10/7/2014 9:22:34 AM